Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chrono-individualized Tacrolimus Dosing in Kidney Transplant Recipients
NCT07877103Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 4, randomised trial of tacrolimus + Wuzhi capsule in end stage renal disease (ESRD) (2 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Incidence of acute rejection (biopsy-proven or clinically diagnosed) at 1 year and Change in graft renal function (eGFR) at 1 year. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT07877103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07877103.